Pal-GHK Limited Evidence

What It Is

Pal-GHK is the International Nomenclature of Cosmetic Ingredients (INCI) name "Palmitoyl Tripeptide-1" — a synthetic lipopeptide in which a palmitic acid residue (16-carbon saturated fatty acid) is covalently linked to the N-terminal amino group of the human tripeptide Gly-His-Lys (GHK). The molecule has an approximate molecular weight of 578.82 Da and is typically supplied as a white to off-white powder that is solubilized in water/butylene-glycol/glycerin gel carriers for cosmetic formulation.

The parent tripeptide GHK was first isolated from human plasma by Loren Pickart in 1973 as a factor that caused older human liver tissue to synthesize proteins more characteristic of younger tissue. GHK has an extraordinarily high affinity for copper(II), forming the naturally occurring complex GHK-Cu that is present in human plasma, saliva, and urine and declines with age — a compound now widely used as the injectable/topical peptide GHK-Cu (a separate profile on this site). The palmitoylated form, Pal-GHK, was developed by Sederma (a subsidiary of Croda International, France) as a cosmetic-grade derivative of GHK designed specifically for topical penetration, stability on the skin surface, and formulation compatibility with the lipid-rich stratum corneum.

The defining commercial context for Pal-GHK is Matrixyl 3000 — Sederma's flagship anti-aging active, launched in the early-2000s as a successor to Matrixyl (Palmitoyl Pentapeptide-4 / Pal-KTTKS). Matrixyl 3000 is a 1:1 pairing of Pal-GHK (Palmitoyl Tripeptide-1) with Palmitoyl Tetrapeptide-7 (Pal-GQPR / Pal-Gly-Gln-Pro-Arg), the latter a tetrapeptide derived from the immunoglobulin IgG sequence with reported anti-inflammatory effects. The two peptides are combined at low concentration in a glycerin/water/butylene-glycol carrier gel and sold to cosmetic formulators as a raw material. Consumer products (serums, creams, eye products) use Matrixyl 3000 at typical recommended use levels of 3–8% of the final formulation, which corresponds to parts-per-million (ppm) concentrations of the actual active peptides in the finished product.

Pal-GHK occupies a specific niche in the cosmetic peptide landscape: it is not a novel structure so much as a delivery-engineered version of an endogenous molecule. The "signal" — the GHK head group — is identical to the GHK that the body already produces and that GHK-Cu delivers systemically. The "vehicle" — the palmitoyl chain — is a lipidation strategy borrowed from Sederma's earlier Matrixyl (Pal-KTTKS) to solve the problem of topical delivery: unmodified GHK is hydrophilic and does not partition efficiently into the lipid-rich stratum corneum. Palmitoylation increases lipophilicity enough to allow penetration while preserving the biologically active GHK head group that engages fibroblast signaling once it reaches the viable epidermis and dermis. The trade-off is that Pal-GHK is supplied as the free (non-copper-chelated) ligand rather than as the pre-formed GHK-Cu complex, and any copper-dependent activity depends on the peptide acquiring copper from endogenous skin reserves (serum copper, ceruloplasmin, metallothionein, or cosmetic co-ingredients) after penetration.

Mechanism of Action

Pal-GHK's proposed mechanism combines delivery pharmacology (the palmitoyl chain) with signaling pharmacology (the GHK head group). Because the GHK signaling repertoire is the same as GHK-Cu, the published mechanistic literature on GHK and GHK-Cu is directly relevant — with the important caveat that most mechanistic characterization has been performed on GHK or GHK-Cu rather than on Pal-GHK specifically, and translation between the palmitoylated and non-palmitoylated forms assumes (but has not always formally demonstrated) equivalent downstream signaling once the GHK head group is exposed in the dermis.

• Palmitoylation-driven stratum corneum permeation — The 16-carbon palmitic acid tail converts hydrophilic GHK into an amphiphilic lipopeptide. The palmitoyl chain partitions into intercellular lipid lamellae of the stratum corneum, enabling the peptide to traverse the primary permeability barrier. This lipidation strategy was first validated for cosmetic matrikines in Matrixyl (Pal-KTTKS), and the same rationale is applied to Pal-GHK. Unmodified GHK has limited topical permeation; palmitoylation is what makes topical delivery pharmacologically plausible (Lintner and Peschard, Int J Cosmet Sci 2000; Robinson et al. 2005 for the Pal-KTTKS precedent).
• Matrikine signaling at the fibroblast — The GHK sequence (Gly-His-Lys) is a matrikine — a bioactive peptide fragment derived from, and mimicking, the proteolytic degradation products of extracellular matrix macromolecules (in GHK's case, collagen type I α2 chain). Matrikines bind cell-surface receptors belonging to the cytokine, chemokine, and growth-factor receptor families and signal cells to initiate repair programs (Maquart et al. 2004; Ricard-Blum and Salza, Exp Dermatol 2014, PMID 24815015). The GHK head group of Pal-GHK, once delivered to the dermis, engages this signaling in dermal fibroblasts.
• Collagen I and III upregulation — The core documented activity. Cell-culture studies of GHK and GHK-Cu consistently demonstrate dose-dependent upregulation of collagen type I and collagen type III synthesis in human dermal fibroblasts, with peak effects typically in the 0.1–1.0 μM range (Maquart et al., FEBS Lett 1988, PMID 3138181 — the foundational finding; subsequent confirmations across multiple groups).
• Fibronectin, decorin, and glycosaminoglycan synthesis — Beyond collagen, the GHK head group stimulates fibroblast production of fibronectin (an ECM glycoprotein that organizes collagen fibrils), decorin (a small leucine-rich proteoglycan that regulates collagen fibrillogenesis), and glycosaminoglycans including hyaluronic acid and dermatan sulfate. The aggregate effect is an ECM-remodeling program rather than stimulation of a single protein (Pickart 2008, PMID 18644225; Pickart, Vasquez-Soltero, Margolina, BioMed Res Int 2015, PMID 26236730).
• Endogenous copper coordination — the GHK-Cu formation hypothesis — Pal-GHK as supplied is the free ligand (peptide without copper). Once in the dermis, the high copper affinity of the GHK sequence means that under physiological conditions the peptide can acquire copper(II) from endogenous skin reserves — primarily albumin-bound and ceruloplasmin-bound copper — to form in situ a GHK-Cu-like complex. Whether Pal-GHK generates true GHK-Cu physiologically or whether the palmitoyl moiety perturbs copper coordination is not fully characterized in the peer-reviewed literature; manufacturer Sederma positions Pal-GHK as a "copper-peptide precursor" on this hypothesis.
• TGF-β pathway engagement — GHK-Cu has been reported to engage the transforming growth factor beta (TGF-β) pathway, a central regulator of fibroblast-driven ECM synthesis. TGF-β signaling is considered part of the mechanistic basis for collagen and fibronectin upregulation observed with GHK-family peptides, and this is extrapolated to Pal-GHK via the shared GHK head group.
• Anti-inflammatory cytokine modulation — GHK and GHK-Cu dampen TNF-α-driven IL-6 secretion in normal human dermal fibroblasts at low concentrations (Gruchlik et al., Acta Pol Pharm 2012, PMID 23285694). This anti-inflammatory profile is one reason Pal-GHK is positioned for aging-skin formulations, where chronic low-grade inflammation ("inflammaging") contributes to ECM degradation.
• Antioxidant / anti-glycation signaling — GHK-Cu has documented activity as a modulator of oxidative stress and a suppressor of lipid peroxidation (Pickart, Vasquez-Soltero, Margolina, Oxid Med Cell Longev 2012, PMID 22666519). By extension, Pal-GHK is proposed to contribute antioxidant activity to topical formulations, though direct measurement of antioxidant activity for Pal-GHK specifically is less well documented than for the parent GHK-Cu.
• Gene-expression reprogramming (Connectivity Map analyses) — Large-scale transcriptomic analyses of GHK/GHK-Cu using the Broad Institute Connectivity Map identified modulation of thousands of genes spanning ECM synthesis, DNA repair, apoptosis regulation, and antioxidant enzymes — a signature interpreted as a "genome-reset" toward a younger-tissue transcriptional profile (Pickart and Margolina, Int J Mol Sci 2018, PMID 29986520). These findings are reported for GHK/GHK-Cu; Pal-GHK is presumed to engage the same pathways upon dermal delivery but has not been independently profiled at the transcriptomic level.
• What Pal-GHK does not do — It does not inhibit matrix metalloproteinases directly, does not scavenge free radicals at the level of classical antioxidants (tocopherol, ascorbate), does not modulate melanogenesis measurably at cosmetic concentrations, and does not act on muscle contraction pathways (distinguishing it from argireline / acetyl hexapeptide-8). Claims beyond matrikine-mediated ECM remodeling should be treated with skepticism.

What the Research Shows

The research base for Pal-GHK has two characteristic problems that must be acknowledged at the outset: most of the direct human data comes from studies of Matrixyl 3000 (the Pal-GHK + Pal-GQPR combination), making it structurally impossible to isolate the effect of Pal-GHK from Pal-GQPR; and much of the clinical-looking data is manufacturer-generated (Sederma/Croda) without independent replication in peer-reviewed high-impact venues.

• Foundational matrikine precedent — Pal-KTTKS (Robinson 2005) — The landmark proof-of-concept for palmitoylated matrikine cosmetics is the Robinson et al. (International Journal of Cosmetic Science 2005; 27(3):155-160) 12-week double-blind split-face placebo-controlled trial in 93 Caucasian women aged 35–55 with photoaged facial skin. This trial studied Pal-KTTKS (Palmitoyl Pentapeptide-4, the active in the original Matrixyl — not Pal-GHK), but established that palmitoyl-peptide matrikines applied topically at parts-per-million concentrations can produce statistically significant reductions in fine lines and wrinkles by both quantitative image analysis and expert-grader assessment. Pal-GHK's development rationale extends this precedent to a different matrikine head group.
• Osborne 2005 pal-KTTKS supporting data — Osborne et al. (J Am Acad Dermatol 2005) reported an 8-week double-blind split-face study of Pal-KTTKS-containing moisturizer in women aged 35–65, corroborating Robinson's findings on fine-line and wrinkle appearance. Again, this is the Matrixyl precursor — not Pal-GHK — but establishes the topical-matrikine performance envelope.
• Matrixyl 3000 manufacturer data (Sederma technical dossier) — Sederma's internal clinical trials of Matrixyl 3000 (the Pal-GHK + Pal-GQPR combination) report reductions in wrinkle volume, wrinkle density, and wrinkle depth of approximately 20–45% over 56–84 days of twice-daily application at 3% Matrixyl 3000 in the finished formula. These results are reported in trade press, ingredient-supplier technical dossiers, and derivative marketing materials; they have not been published as independent peer-reviewed clinical trials in high-impact dermatology journals.
• Mas-Chamberlin / Lintner 2002 conference data — Mas-Chamberlin, Lintner, Basset et al. (Ann Dermatol Venereol 2002, 20th World Congress of Dermatology conference proceedings) reported a 4-month clinical double-blind study of a palmitoyl-peptide-containing antiwrinkle treatment versus excipient control, forming part of the early clinical dataset underlying Sederma's Matrixyl family of actives.
• GHK-Cu clinical data as mechanistic support — Cosmetic studies of GHK-Cu-containing creams (separate from Pal-GHK) report improvements in skin thickness, elasticity, and wrinkle depth in aged skin (Leyden et al., Abdulghani et al., Finkley et al. — classical GHK-Cu facial cream studies cited across the copper-peptide cosmetic literature). These are adduced as supporting evidence for Pal-GHK on the mechanistic premise that the active signaling moiety (GHK) is the same and that Pal-GHK generates GHK-Cu-like activity in situ.
• In vitro fibroblast studies (multiple) — Cell-culture studies using Pal-GHK or GHK at fibroblast-relevant concentrations (0.1–10 μM) demonstrate increases in procollagen synthesis, fibronectin deposition, and glycosaminoglycan secretion. Reported effect magnitudes range from modest (15–30%) to substantial (2-fold or greater) depending on experimental conditions, control comparator, and end-point timing.
• Pal-GHK + cosmetic-excipient formulation studies — Published in vivo cosmetic-science literature (e.g., Vaillant-Ciszewicz and others in the instrumental-evaluation literature) has evaluated facial/eye-cream formulations containing palmitoyl peptides alongside Silybum marianum seed oil, vitamin E, and other functional ingredients, reporting improvements in skin wrinkles, elasticity, and dermal density over 4-week application windows. These studies evaluate multi-ingredient cosmetic formulations; the isolated Pal-GHK contribution is not cleanly attributable.
• Negative / null findings — The published negative-finding record for Pal-GHK specifically is thin because most negative trials of matrikine cosmetic ingredients do not reach peer-reviewed publication; absence of negative data should be interpreted cautiously rather than as confirmation of efficacy. Independent meta-analyses of cosmetic peptide efficacy have repeatedly flagged the "manufacturer-sponsorship-plus-missing-independent-replication" pattern across the matrikine class.

Human Data

Human data for Pal-GHK is predominantly formulation-level (Matrixyl 3000-containing products) rather than isolated peptide-monotherapy. The following is a representative summary of the human-subject research base, organized from most directly relevant to mechanistic-support:

• Robinson 2005 — Pal-KTTKS, photoaged facial skin (Int J Cosmet Sci 2005; 27(3):155-160) — 12-week double-blind split-face placebo-controlled study in 93 Caucasian women aged 35–55. Pal-KTTKS at 3 ppm in a moisturizer cream vs moisturizer-only control. Statistically significant improvements in wrinkles/fine lines vs placebo by quantitative image analysis and expert-grader assessment. This trial established the palmitoylated-matrikine proof-of-concept on which Pal-GHK formulations are marketed; the active peptide is Pal-KTTKS (not Pal-GHK).
• Osborne 2005 — Pal-KTTKS moisturizer (J Am Acad Dermatol 2005) — 8-week double-blind split-face randomized study in women aged 35–65. Pal-KTTKS-containing moisturizer vs placebo moisturizer. Reported improvements in bumpy texture, fine lines, and wrinkle appearance. Same family of molecule as Pal-GHK, same signaling class (matrikine), different peptide.
• Mas-Chamberlin / Lintner 2002 — palmitoyl-peptide antiwrinkle study (Ann Dermatol Venereol) — 4-month clinical double-blind study vs excipient, presented at the 20th World Congress of Dermatology, Paris 2002. Cited extensively in Sederma's technical dossiers as part of the early clinical base for the Matrixyl matrikine family.
• Sederma Matrixyl 3000 (Pal-GHK + Pal-GQPR) internal trials — Reported in trade and technical-supplier literature: 2-month double-blind clinical trials with 23 volunteers applying Matrixyl 3000 formulations at 3% in the finished cream twice daily, measuring wrinkle volume, wrinkle density, and wrinkle depth at days 28 and 56. Reported reductions of approximately 20–45% across the measured parameters vs placebo. Not published as a peer-reviewed clinical trial in a mainstream dermatology journal.
• Instrumental-evaluation facial-cream studies (palmitoyl-peptide blends) — Published cosmetic-science literature has evaluated facial and eye-cream formulations containing palmitoyl peptides alongside botanical extracts (Silybum marianum), vitamin E, and other cosmetic actives, reporting improvements in wrinkles, elasticity, and dermal density over 4-week application periods using instrumental skin bioengineering techniques (Cutometer, Reviscometer, Dermascan, corneometer).
• Related — Palmitoyl Pentapeptide-4 (Matrixyl / Pal-KTTKS) ongoing clinical literature — Multiple subsequent in-vivo cosmetic trials across 2005–2020 have used Pal-KTTKS as a comparator or co-active; these inform the topical-matrikine literature but do not add direct Pal-GHK human data.
• Related — GHK-Cu cream facial studies — Classical GHK-Cu cosmetic trials (Leyden, Abdulghani, Finkley — widely cited across the copper-peptide literature) report improvements in skin thickness, elasticity, and wrinkles over 12-week application windows. These are GHK-Cu — not Pal-GHK — and are cited as mechanistic support rather than direct Pal-GHK evidence.
• No FDA-monitored clinical-trial database entry for Pal-GHK — ClinicalTrials.gov does not contain a registered interventional trial of Pal-GHK monotherapy as of April 2026. As a cosmetic ingredient rather than a drug, Pal-GHK has not been evaluated through the investigational new drug (IND) / clinical-trial pathway.
• Honest assessment — The human evidence base for Pal-GHK specifically is limited. The matrikine-cosmetic class has better-quality data, but most of that data is for Pal-KTTKS (the original Matrixyl) rather than Pal-GHK. The Matrixyl 3000 data cannot isolate the Pal-GHK component. The mechanistic case for Pal-GHK as a topical GHK-Cu-precursor is scientifically reasonable; the clinical-efficacy case is extrapolated and supported primarily by manufacturer-generated data.

Dosing from the Literature

Pal-GHK is a topical-only cosmetic ingredient. It is not injected, not taken orally, not reconstituted in bacteriostatic water, and not compounded in peptide compounding pharmacies for systemic use. Dosing is formulation-level (concentration of the active in the finished product), not dose-level (milligrams per kilogram).

Reconstitution & Storage

Pal-GHK is not a lyophilized injectable peptide and does not require bacteriostatic-water reconstitution. Supply forms vary: Matrixyl 3000 is supplied as a pre-made gel or aqueous solution (carrier = glycerin, water, butylene glycol, carbomer, polysorbate 20, with Pal-GHK and Pal-GQPR as active ingredients); isolated Pal-GHK raw material is supplied as a white-to-off-white powder that requires solubilization before use in a cosmetic base.

• pH stability — Pal-GHK is most stable in slightly acidic to neutral formulations (pH 4.5–6.5). Alkaline formulations (pH > 7.5) can degrade the peptide via imidazole ring tautomerization at the histidine residue and amide-bond hydrolysis.
• Oxidative stability — Copper-binding peptides can catalyze Fenton-type chemistry in the presence of free copper and hydrogen peroxide. Formulators typically pair Pal-GHK with chelators (EDTA, phytic acid) and antioxidants (tocopherol, ascorbyl tetraisopalmitate) to prevent oxidative degradation of the peptide and the formulation.
• Preservative compatibility — Pal-GHK is generally compatible with modern cosmetic preservatives (phenoxyethanol, ethylhexylglycerin, benzyl alcohol, DMDM hydantoin). Some formaldehyde-donor preservatives and strongly cationic preservatives can destabilize peptides over long shelf life.
• Temperature — Avoid adding Pal-GHK to the hot phase of emulsion manufacturing. Always add to the cool-down phase, typically below 40°C and ideally below 30°C.
• Packaging — Opaque, airless pumps maximize peptide stability. Jars that are repeatedly opened to air and light shorten the active shelf life of peptide formulations.
• Consumer use — Finished Pal-GHK-containing products should be stored below 25°C, kept capped between uses, and used within the manufacturer's period-after-opening (PAO) symbol indication (typically 6–12 months).

→ Use the Kalios Dosing Calculator for formulation-concentration conversions

Side Effects & Risks

Pal-GHK has a favorable safety profile consistent with other low-molecular-weight topical cosmetic peptides. No significant systemic toxicity has been reported at cosmetic use concentrations. The principal risk vectors are formulation-level irritancy, allergic contact dermatitis to the peptide or excipients, and (theoretical) pro-oxidant behavior in the presence of excess free copper.

• Irritation / contact dermatitis — Reported rates are very low at cosmetic Matrixyl 3000 use levels (3–8%). Most reported reactions in consumer products containing Pal-GHK are traceable to excipients (fragrances, preservatives, botanical extracts) rather than to the peptide itself.
• Allergic contact dermatitis — Theoretically possible but rare. Patients with prior allergic reactions to cosmetic peptides or to palmitic-acid-based ingredients (palmitate esters) should patch-test before full-face application.
• Photosensitivity — Not reported with Pal-GHK. Unlike some retinoid-class actives, Pal-GHK does not increase photosensitivity. Sunscreen is nevertheless recommended as a general anti-aging adjunct.
• Pregnancy and lactation — Topical cosmetic peptides are generally considered low-risk in pregnancy due to negligible systemic absorption, but formal pregnancy-safety data for Pal-GHK specifically is absent. Consult a licensed obstetric / dermatology provider before use during pregnancy or lactation.
• Pediatric use — Anti-aging cosmetic peptides are not intended for pediatric use; there is no pediatric research base for Pal-GHK.
• Copper-overload theoretical concern — Because Pal-GHK binds copper with high affinity and may form GHK-Cu in situ, individuals with disorders of copper metabolism (Wilson disease, Menkes disease) should consult a medical geneticist / hepatologist before repeated use. The copper delivered via cosmetic Pal-GHK concentrations is trivial compared to dietary copper intake, but the theoretical point should be noted.
• Pro-oxidant potential in poorly formulated products — Free copper + Pal-GHK + hydrogen peroxide or unsaturated lipids can accelerate lipid peroxidation in unstable formulations. Well-formulated Pal-GHK cosmetics include chelators and antioxidants to prevent this; poorly formulated products may show oxidation (color change, odor change) during the use period.
• Combination with acids (AHAs, BHAs, vitamin C) — Layering Pal-GHK with low-pH exfoliating acids or pure L-ascorbic acid can shift the skin-surface microenvironment below the peptide's stability range. Most dermatology-informed routines apply Pal-GHK / Matrixyl 3000 products separately from acids (e.g., acid in the AM, peptide in the PM), though same-routine use is not contraindicated in most well-buffered commercial products.
• Interaction with other actives — No significant reported interactions with tretinoin, niacinamide, hyaluronic acid, azelaic acid, or ceramide-based products at cosmetic concentrations. Pal-GHK is typically additive with these in a multi-step routine.
• Systemic effects — None expected at cosmetic use concentrations. The systemic absorption of lipopeptides at typical application levels is below the threshold for measurable pharmacokinetic effect; circulating GHK/GHK-Cu levels are regulated primarily by endogenous synthesis and dietary factors, not by topical cosmetic exposure.
• Long-term safety — Decades of cosmetic use of Matrixyl 3000 and Pal-GHK across the cosmetic industry have not surfaced novel long-term safety signals. The compound is considered "generally recognized as safe" for cosmetic application within the use-level range specified in supplier technical documentation.

Bloodwork & Monitoring

Pal-GHK is a topical cosmetic ingredient with negligible systemic absorption at use concentrations. Bloodwork is not indicated. Monitoring is dermatological and observational rather than laboratory-based.

• No routine bloodwork — Topical cosmetic peptides at cosmetic concentrations do not produce measurable changes in standard laboratory chemistry, hematology, or copper status. CBC, CMP, serum copper, and ceruloplasmin are not required before or during use of Pal-GHK cosmetics.
• Patch testing — The most valuable pre-use test is a 48-hour patch on the inner forearm or behind the ear to rule out individual irritant or allergic response to the finished formulation. Apply twice daily for 3 days before full-face use.
• Photographic tracking — Standardized before/after photography under consistent lighting conditions is the single most useful outcome measure for any cosmetic peptide. Recommended: monthly photographs at consistent distance, lighting, and expression for 3–6 months to assess wrinkle depth, skin tone, and texture response.
• Cutometer / skin-bioengineering assessments — In clinical-research settings, Cutometer (elasticity), Reviscometer (anisotropy), Dermascan (dermal echogenicity / density), and corneometer (hydration) are the instrumental measures used to quantify topical-peptide response. These are dermatology-office or research-laboratory tools, not at-home metrics.
• Subjective assessments — Participant-rated scales (self-assessed facial skin quality, wrinkle severity, overall appearance) show meaningful correlation with instrumental measures in the Matrixyl 3000 clinical literature and are a reasonable consumer proxy.
• Skin allergy / sensitivity — If a new Pal-GHK-containing product produces erythema, burning, persistent itch, or dermatitis, discontinue and consult a dermatologist. Patch-test individual suspected ingredients if multiple new products were introduced simultaneously.
• Interaction with in-office procedures — Standard practice is to pause topical peptide products 24–48 hours before and after laser, microneedling, chemical peel, or other ablative procedures. Resume after the skin barrier has re-formed per the treating clinician's guidance.

Commonly Stacked With

Pal-GHK is rarely used alone. The canonical "stack" is within Matrixyl 3000 itself (Pal-GHK + Pal-GQPR). Beyond that, cosmetic routines typically layer Pal-GHK-containing products alongside complementary actives. The calculator's stack compatibility engine does not apply to topical cosmetic peptides (which are dosed by formulation concentration, not by injected milligram-per-kilogram); the cosmetic "stacking" logic is formulation-layering compatibility.

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

Palmitoyl-tripeptide siblings and GHK-family actives:

Next Steps

Key References

1. Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. International Journal of Cosmetic Science. 2005;27(3):155-160. doi:10.1111/j.1467-2494.2005.00261.x. PMID: 18492182. (Foundational 12-week double-blind split-face RCT in 93 women aged 35–55; established the topical palmitoyl-matrikine proof-of-concept on which the Matrixyl / Matrixyl 3000 family — including Pal-GHK — is marketed.)
2. Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988. doi:10.1163/156856208784909435. PMID: 18644225. (Foundational review of the parent tripeptide GHK, its tissue-remodeling biology, and the copper-coordination mechanism underlying GHK-Cu signaling — directly relevant to Pal-GHK's proposed in situ GHK-Cu formation.)
3. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108. PMID: 26236730; PMC4508379. (Comprehensive review of GHK's multi-pathway skin-regenerative signaling — collagen, fibronectin, decorin, GAGs, anti-inflammatory, antioxidant effects — all of which are extrapolated to Pal-GHK on the shared head-group argument.)
4. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID: 29986520; PMC6073405. (2018 gene-expression-based review using Broad Institute Connectivity Map data; demonstrates GHK-Cu modulation of thousands of genes across ECM synthesis, DNA repair, apoptosis, and antioxidant pathways.)
5. Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxidative Medicine and Cellular Longevity. 2012;2012:324832. PMID: 22666519. (Mechanistic foundation for antioxidant / oxidative-stress modulation; extrapolated to Pal-GHK via shared GHK head group.)
6. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988;238(2):343-346. doi:10.1016/0014-5793(88)80509-x. PMID: 3138181. (The foundational in vitro demonstration of GHK-Cu-driven fibroblast collagen synthesis — the mechanism that Pal-GHK is hypothesized to engage in situ after palmitoyl-delivery to the dermis.)
7. Ricard-Blum S, Salza R. Matricryptins and matrikines: biologically active fragments of the extracellular matrix. Experimental Dermatology. 2014;23(7):457-463. doi:10.1111/exd.12435. PMID: 24815015. (Modern framework paper defining the matrikine / matricryptin class to which GHK and Pal-GHK belong.)
8. Maquart FX, Pasco S, Ramont L, Hornebeck W, Monboisse JC. An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity. Implication in tumor invasion. Critical Reviews in Oncology/Hematology. 2004;49(3):199-202. doi:10.1016/j.critrevonc.2003.06.007. (Seminal review introducing the matrikine concept; the theoretical foundation for palmitoyl-matrikine cosmetic actives.)
9. Osborne R, Robinson LR, Mullins L, Raleigh P. Use of a facial moisturizer containing palmitoyl pentapeptide improves the appearance of aging skin. Journal of the American Academy of Dermatology. 2005;52(3 Suppl):P43. (Supporting 8-week split-face human data on the palmitoyl-pentapeptide Matrixyl, the direct precursor to Matrixyl 3000 / Pal-GHK.)
10. Mas-Chamberlin C, Lintner K, Basset L, Adhoute H, Revuz J. Relevance of antiwrinkle treatment of a peptide: 4 months clinical double blind study vs excipient. Annales de Dermatologie et de Vénéréologie. 2002;129(1S):456. Proceedings, 20th World Congress of Dermatology, Paris. (Early clinical data on the Sederma palmitoyl-peptide program that seeded the Matrixyl and Matrixyl 3000 actives.)
11. Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. International Journal of Cosmetic Science. 2000;22(3):207-218. doi:10.1046/j.1467-2494.2000.00010.x. (Sederma researcher review of the palmitoyl-peptide lipidation-for-permeation strategy that underlies Pal-GHK delivery pharmacology.)
12. Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sciences. 2017;7(2):20. doi:10.3390/brainsci7020020. PMID: 28241430. (Extension of GHK transcriptomic effects; relevant to Pal-GHK only indirectly via shared head group.)
13. Gruchlik A, Jurzak M, Chodurek E, Dzierzewicz Z. Effect of Gly-Gly-His, Gly-His-Lys and their copper complexes on TNF-alpha-dependent IL-6 secretion in normal human dermal fibroblasts. Acta Poloniae Pharmaceutica. 2012;69(6):1303-1306. PMID: 23285694. (Direct anti-inflammatory cytokine data for the GHK head group and its copper complex in dermal fibroblasts.)
14. Pickart L, Margolina A. Skin Regenerative and Anti-Cancer Actions of Copper Peptides. Cosmetics. 2018;5(2):29. doi:10.3390/cosmetics5020029. (Contemporary MDPI Cosmetics review of copper-peptide skin biology applicable to the Pal-GHK-in-situ-GHK-Cu formation hypothesis.)
15. Finkley MB, Appa Y, Bhandarkar S. Copper peptide and skin. Cosmeceuticals and Active Cosmetics: Drugs vs. Cosmetics. Marcel Dekker, New York; 2005:549–563. (Classical cosmetic-dermatology chapter summarizing GHK-Cu-containing facial cream clinical data — the cream data most often cited as mechanistic support for Pal-GHK cosmetic efficacy.)
16. Abdulghani AA, Sherr A, Shirin S, Solodkina G, Tapia EM, Wolf B, Gottlieb AB. Effects of topical creams containing vitamin C, a copper-binding peptide cream, and melatonin compared with tretinoin on the ultrastructure of normal skin: a pilot clinical, histologic, and ultrastructural study. Disease Management & Clinical Outcomes. 1998;1(4):136-141. (Copper-peptide cream ultrastructural skin-effect data used throughout the copper-peptide cosmetic literature as supporting evidence.)
17. Leyden JJ, Stephens T, Finkey MB, Appa Y, Barkovic S. Skin breakdown in adult diapers. Poster presentation, 60th Annual Meeting American Academy of Dermatology; February 22–27, 2002; New Orleans, LA. (Copper-peptide facial cream clinical data, part of the Neova / ProCyte GHK-Cu development package.)
18. Sederma (Croda International). Matrixyl 3000 technical dossier and product information sheets. Sederma, Le Perray-en-Yvelines, France. 2003–2024. (Manufacturer's technical documentation for the Pal-GHK + Pal-GQPR combination active — the primary source for recommended use levels, stability data, and unpublished in-house clinical trials on wrinkle volume / density / depth reductions at 3% Matrixyl 3000 over 56-day protocols.)
19. European Commission. CosIng — Cosmetic Ingredient Database entry: Palmitoyl Tripeptide-1. (Official EU regulatory listing confirming cosmetic ingredient status in the EU single market.)
20. U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act — Cosmetic Product Ingredient Regulatory Framework. (Regulatory context for topical cosmetic peptides including Palmitoyl Tripeptide-1; FDA does not pre-approve cosmetic ingredients but monitors adulteration and misbranding.)